Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients

Saudi Journal of Gastroenterology

Volumn 14, Issue 3, 2008, Pages 151-157

  Danish, Fazal ^a   Koul, Salman ^b   Subhani, Fazal ^c   Rabbani, Ahmed ^d   Yasmin, Saeeda ^e,f  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b PAKISTAN INSTITUTE OF MEDICAL SCIENCES   (Pakistan)

^c HOLY FAMILY HOSPITAL   (Pakistan)

^d FOUNDATION UNIVERSITY MEDICAL COLLEGE   (Pakistan)

^e Rawalpindi General Hospital   (Pakistan)

^f NONE   (Pakistan)

Author keywords

Chronic Hepatitis C; Hematopoietic growth factors; Hemolytic anemia; Neutropenia

Indexed keywords

EID: 46949105267     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.41739     Document Type: Review

References (78)

1. Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis 2003;37:315-22.
2. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003;37:533-41.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65.
4. Hadziyannis SJ, Papatheodoridis GV. Peginterferonalpha2a (40 kDa) for chronic hepatitis C. Exp Opin Pharmacother 2003;4:541-51.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
6. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002;123:141-51.
7. Lebray P, Nalpas B, Vallet-Pichard A, Broissand C, Sobesky R, Serpaggi J, et al. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antivir Ther 2005;10:769-76.
8. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, et al. Management of chronic hepatitis C: Consensus guidelines. Can J Gastroenterol 2007;21:25C-34C.
9. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
10. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. J Clin Oncol 2008;26:132-49.
11. Rebetol (RBV, USP) product information. Kenilworth, NJ: Schering Corporation; 2003.
12. Tanaka N, Ishida F, Tanaka E. Ribavirin-induced pure red-cell aplasia during treatment of chronic hepatitis C. N Engl J Med 2004;350:1264-5.
13. Balan V, Wu GY, Muir AJ, Keeffe EB, Bowers PJ. Erythropoietin response to anemia is decreased in patients infected with hepatitis C virus (HCV) receiving combination therapy and PEG-IFN (RBV/PEG-IFN) therapy. Gastroenterology 2003;124:M1417.
14. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alpha maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized, control study. Gastroenterology 2004;126:1302-11.
15. Maddrey WC. Safety of combination interferon alfa-2b/RBV therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999;19:67-75.
16. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: Alpha interferon and ribavirin. Hepatology 1997;26:108S-11S.
17. Chapko MK, Dominitz JA. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. Aliment Pharmacol Ther 2006;24:1067-77.
18. Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40:1450-8.
19. Thevenot T, Di Martino V, Lunel-Fabiani F, Vanlemmens C, Becker MC, Bronowicki JP, et al. Complementary treatments of chronic viral hepatitis C. Gastroenterol Clin Biol 2006;30:197-214.
20. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
21. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and RBV combination therapy in chronic hepatitis C: A randomized study of treatment duration and RBV dose. Ann Intern Med 2004;140:346-55.
22. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9.
23. Shiffman ML, Price A, Hubbard S. Treatment of chronic hepatitis C virus (HCV) genotype 1 with peginterferon alpha-2B (PEGIFN), high weight based dose ribavirin (RVN) and Epoetin alpha (EPO) enhances sustained virologic response (SVR). Hepatology 2005;42:217A.
24. Talal AH, Weisz K, Hau T, Kreiswirth S, Dieterich DT. A preliminary study of erythropoietin for anemia associated with RBV and interferon-alpha. Am J Gastroenterol 2001;96:2802-4.
25. Gergely AE, Lafarge P, Fouchard-Hubert I, Lunel-Fabiani F. Treatment of RBV/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology 2002;35:1281-2.
26. Younossi ZM, Ong JP, Collantes R, Assmann JS, Sjogren R, Sjogren M, et al. Darbepoetin alpha (DA) for RBV-induced anemia in patients with chronic hepatitis C (CH-C) treated with PEG-IFN and RBV (PEG-IFN/RBV): A preliminary analysis. Gastroenterology 2004;126:83A.
27. Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: A randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2004;20:437-43.
28. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23.
29. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peg interferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
30. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5:124-9.
31. Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clin Ther 2006;28:801-31.
32. Seidenfeld J, Piper M, Bohlius J. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Comparative Effectiveness Review No. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026.) Agency for Healthcare Research and Quality, 2006.
33. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987;316:73-8.
34. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 1989;111:992-1000.
35. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes: Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998;103:1070-4.
36. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
37. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
38. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007;356:2445-8.
39. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-7.
40. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-42.
41. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 2007;21:627-32.
42. Bunn HF. Drug-induced autoimmune red-cell aplasia. N Engl J Med 2002;346:522-523.
43. Stravitz RT, Chung H, Sterling RK, Luketic VA, Sanyal AJ, Price AS, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005;100:1415-9.
44. Food and Drug Administration. Oncologic Drugs Advisory Committee Briefing Document. Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, LP, for the Treatment of Anemia Associated with Cancer Chemotherapy. 2004.
45. ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15:174-82.
46. Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999;80:396-402.
47. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24.
48. Bohlius J, Wilson J, Seidenfeld J. Erythropoietin or darbepetin for patients with cancer (review). The Cochrane Library Issue 2, 2007.
49. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-72.
50. Henke M, Laszig R, Rube C, Schäfer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
51. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-32.
52. Zsebo KM, Cohen AM, Murdock DC, Boone TC, Inoue H, Chazin VR, et al. Recombinant human granulocyte colony-stimulating factor: Molecular and biological characterization. Immunobiology 1986;172:175-84.
53. Welte K, Bonilla MA, Gillio AP, Boone TC, Potter GK, Gabrilove JL, et al. Recombinant human G-CSF: Effects on hematopoiesis in normal and cyclophosphamide treated primates. J Exp Med 1987;165:941-8.
54. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-81.
55. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, et al. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 1986;232:61-5.
56. Weisbart RH, Kacena A, Schuh A, Golde DW. GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature 1988;332:647-8.
57. Fukuda A, Kobayashi H, Teramura K, Yoshimoto S, Ohsawa N. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines, Cell Mole Ther 2000;6:149-54.
58. Renou C, Harafa A, Cummins C, Muller P, Demattei C, Jouve E, et al. Threshold for neutropaenia in the adjustment of interferon treatment in HCV infection. Hepatology 2003;37:949-50.
59. Renou C, Harafa A, Bouabdallah R, Demattei C, Cummins C, Rifflet H, et al. Severe neutropaenia and post-hepatitis C cirrhosis treatment: Is interferon dose adaptation at once necessary? Am J Gastroenterol 2002;97:1260-3.
60. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropaenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-9.
61. Shiratori Y, Yokosuka O, Nakata R, Ihori M, Hirota K, Katamoto T, et al. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 1999;29:1573-80.
62. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-36.
63. Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of postliver transplant recurrent hepatitis C. Clin Transplant 2004;18:166-73.
64. Puoti M, Babudieri S, Rezza G, Viale P, Antonini NG, Maida I, et al. Use of PEG-IFNs is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: A side effect of pegylation? Antivir Ther 2004;9:627-30.
65. Koirala J, Gandotra SD, Rao S, Sangwan G, Mushtaq A, Htwe TH, et al. Granulocyte colony-stimulating factor dosing in PEG-IFN alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007;14:782-7.
66. Spiegel BM, Chen K, Chiou CF, Robbins S, Younossi ZM. Erythropoietic growth factors for treatment-induced anemia in hepatitis C: A cost-effectiveness analysis. Clin Gastroenterol Hepatol 2005;3:1034-42.
67. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006;6:1598-606.
68. Peck-Radosavljevic M, Wichlas M, Pidlich J, Sims P, Meng G, Zacherl J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998;28:1424-9.
69. Bordin G, Ballaré M, Zigrossi P, Bertoncelli MC, Paccagnino L, Baroli A, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: A direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995;13:S39-S43.
70. Ballard HS. Hematological complications of alcoholism. Alcohol Clin Exp Res 1989;13:706-20.
71. Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002;97:2040-5.
72. McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol 2000;14:1009-31.
73. Luengo JI, Duffy KJ, Shaw AN. Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. Blood 2004;104:2910.
74. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739-41.
75. Sellers T, Hart T, Semanik M, Murthyl K. Pharmacology and safety of SB-497115-GR, an orally active small molecular weight TPO receptor agonist, in chimpanzees, rats and dogs. Blood 2004;104:2063.
76. Erickson-Miller CL, Luengo JI, Nicholl R. In vitro and in vivo biology of a small molecular weight TPO receptor agonist, SB-497115: Poster presented at the 96th American Association for Cancer Research Annual Meeting, Anaheim, CA, April 16-20, 2005.
77. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-47.
78. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-36.